Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-05-05
2004-02-24
Eyler, Yvonne (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S069100, C435S320100, C435S325000, C530S350000
Reexamination Certificate
active
06696260
ABSTRACT:
FIELD OF THE INVENTION
This invention relates generally to ligand-receptor interactions and more specifically to growth differentiation factor receptor proteins and the ligands that bind to such receptors and methods of use therefor.
DESCRIPTION OF RELATED ART
The transforming growth factor &bgr; (TGF-&bgr;) superfamily encompasses a group of structurally-related proteins which affect a wide range of differentiation processes during embryonic development. The family includes, Mullerian inhibiting substance (MIS), which is required for normal male sex development (Behringer, et al.,
Nature
, 345:167, 1990), Drosophila decapentaplegic (DPP) gene product, which is required for dorsal-ventral axis formation and morphogenesis of the imaginal disks (Padgett, et al.,
Nature
, 325:81-84, 1987), the Xenopus Vg-1 gene product, which localizes to the vegetal pole of eggs ((Weeks, et al.,
Cell
, 51:861-867, 1987), the activins (Mason, et al.,
Biochem, Biophys. Res. Commun
., 135:957-964, 1986), which can induce the formation of mesoderm and anterior structures in Xenopus embryos (Thomsen, et al.,
Cell
, 63:485, 1990), and the bone morphogenetic proteins (BMPS, osteogenin, OP-1) which can induce de novo cartilage and bone formation (Sampath, et al.,
J. Biol. Chem
., 265:13198, 1990). The TGF-&bgr;s can influence a variety of differentiation processes, including adipogenesis, myogenesis, chondrogenesis, hematopolesis, and epithelial cell differentiation (for review, see Massague,
Cell
49:437, 1987).
The proteins of the TGF-&bgr; family are initially synthesized as a large precursor protein which subsequently undergoes proteolytic cleavage at a cluster of basic residues approximately 110-140 amino acids from the C-terminus. The C-terminal regions, or mature regions, of the proteins are all structurally related and the different family members can be classified into distinct subgroups based on the extent of their homology. Although the homologies within particular subgroups range from 70% to 90% amino acid sequence identity, the homologies between subgroups are significantly lower, generally ranging from only 20% to 50%. In each case, the active species appears to be a disulfide-linked dimer of C-terminal fragments. Studies have shown that when the pro-region of a member of the TGF-&bgr; family is coexpressed with a mature region of another member of the TGF-&bgr; family, intracellular dimerization and secretion of biologically active homodimers occur (Gray, A. et al.,
Science
, 247:1328, 1990). Additional studies by Hammonds, et al., (
Molec. Endocrin
. 5:149, 1991) showed that the use of the BMP-2 pro-region combined with the BMP-4 mature region led to dramatically improved expression of mature BMP-4. For most of the family members that have been studied, the homodimeric species has been found to be biologically active, but for other family members, like the inhibins (Ling, et al.,
Nature
, 321 :779, 1986) and the TGF-&bgr;s (Cheifetz, et al.,
Cell
, 48:409, 1987), heterodimers have also been detected, and these appear to have different biological properties than the respective homodimers.
The study of receptor-ligand interactions has revealed a great deal of information about how cells respond to external stimuli. This knowledge has led to the development of therapeutically important compounds, such as erythropoietin, colony stimulating factors and PDGF.
SUMMARY OF THE INVENTION
The present invention provides receptors for the growth differentiation factor (GDF) growth factor family. These receptors are useful for identifying antagonists and agonists for agricultural and human therapeutic purposes.
In a first embodiment, the invention provides a recombinant cell line that expresses growth differentiation factor-8 (GDF-8) or growth differentiation factor-11 (GDF-11) receptor polypeptide. Also included are antibodies that bind to GDF receptors, polynucleotides encoding the receptors and the GDF receptor proteins themselves.
Peptide fragments of GDF receptors, such as the GDF-8 or GDF-11 receptors, are also included. Such peptides may be useful in inhibiting binding of GDF-8 or GDF-11 to either its own receptor or another GDF-receptor (e.g., GDF-8 and -11 may bind the same receptor).
In another embodiment, the invention provides a substantially purified GDF-8-binding agent, wherein the binding agent inhibits GDF-8 binding to GDF-8 receptor. Such agents that inhibit GDF-11 binding are also included.
In yet another embodiment, the invention provides a method for identifying a GDF receptor polypeptide including incubating components such as GDF polypeptide and a cell expressing a receptor or a soluble receptor under conditions sufficient to allow the GDF to bind to the receptor; measuring the binding of the GDF polypeptide to the receptor; and isolating the receptor.
The invention also includes a method for identifying a compound that binds to GDF receptor polypeptide including incubating components comprising the compound and GDF polypeptide under conditions sufficient to allow the components to interact and measuring the binding or effect of binding of the compound to GDF receptor polypeptide.
The invention also provides non-human transgenic animals that have a phenotype characterized by expression of GDF-receptor polypeptide, the phenotype being conferred by a transgene contained in the somatic and germ cells of the animal, the transgene comprising a nucleic acid sequence which encodes GDF-receptor polypeptide. Methods of producing such transgenic animals are also included.
In another embodiment, the invention includes a method for inhibiting the expression of GDF-receptor in a cell including contacting GDF-receptor with an inhibiting effective amount of an antisense oligonucleotide that binds to a segment of an mRNA transcribed from a GDF-receptor gene, whereby the binding of the antisense to the mRNA segment inhibits GDF-receptor expression.
REFERENCES:
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5885794 (1999-03-01), Mathews et al.
patent: 5994618 (1999-11-01), Lee et al.
patent: 6004937 (1999-12-01), Wood et al.
patent: WO 98/33887 (1998-05-01), None
patent: WO99/06559 (1999-02-01), None
patent: WO99/56768 (1999-11-01), None
Nishitoh et al., J. Biol. Chem. 1996, vol. 271, pp. 21345-21352.*
Hannon et al. J. Cell Biol. 1996, vol. 132, pp. 1151-1159.*
Massague, J. Ann. Rev. Biochem. 1998, vol. 67, pp. 753-791.*
Sutrave et al., “The induction of skeletal muscle hypertrophy by askitransgene is promoter-dependent,”Gene,vol. 241, pp. 107-116 (2000).
Yamamoto et al., “Smad1 and Smad5 Act Downstream of Intracellular Signalings of BMP-2 That Inhibits Myogenic Differentiation and Induces Osteoblast Differentation in C2C12 Myoblast,”Biochemical and Biophysical Research Communications,vol. 238, pp. 574-580 (1997).
McPherron and Lee et al., “Double muscling in cattle due to mutations in the myostatin gene,”Proc. Natl. Acad. Sci USA,vol. 94, pp. 12457-12461, Nov. 1997.
Gamer et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos,”Development Biology,vol. 298, pp. 222-232 (1999).
Berk et al., “Mice Lacking theskiProto-Oncogene Have Defects in Neurulation, Craniofacial Patterning, and Skeletal Muscle Development,”Genes&Development11:2029-2039 (1997).
Böttinger et al., “The Recombinant Proregion of Transforming Growth Factor &bgr;1 (Latency-Associated Peptide) Inhibits Active Transforming Growth Factor &bgr;1 in Transgenic Mice,”Proc. Natl. Acad. Sci93:5877-5882 (1996).
Gamer et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is A Potent Mesoderm Inducer inXenopusEmbryos,”Developmental Biology208: 222-232 (1999).
Gentry and Nash, “The Pro Domain of Pre-Pro-Transforming Growth Factor &bgr;1 When Independently Expressed is a Functional Binding Protein for the Mature Growth Factor,”Biochemistry29:6851-6857 (1990).
Gonzalez-Cadavid et al., “Organization of the Luman Myostatin Gene and Expression in Healthy Men and HIV-Infected Men with Musc
Lee Se-Jin
McPherron Alexandra
Andres Janet L.
Eyler Yvonne
Gray Cary Ware & Freidenrich LLP
Haile Lisa A.
Imbra Richard J.
LandOfFree
Methods to identify growth differentiation factor (GDF)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to identify growth differentiation factor (GDF)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to identify growth differentiation factor (GDF)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3284539